Overview

Overview

The Department of Nephrology and Hypertension within Cleveland Clinic’s Glickman Urological & Kidney Institute has a rich history of innovation and research in hypertension. The Department’s Center for Blood Pressure Disorders provides expertise in hypertension management, and is staffed by American Society of Hypertension (ASH) certified hypertension specialists, with a dedicated hypertension lab for evaluation and testing.

The Department has been designated as a Comprehensive Hypertension Center by the American Society of Hypertension, which recognizes expertise in treating patients who have complex or difficult-to-treat hypertension and its co-morbidities.

The Center follows a collaborative approach to diagnosis, care and monitoring of blood pressure disorders. We work closely with internists, cardiologists, endocrinologists, and vascular medicine specialists to develop a diagnostic and management plan that is tailored to the individual patient. An effective treatment program requires partnership between the patient and care providers. The Center supports patients with information regarding blood pressure monitoring guidelines, lifestyle changes and nutrition.

What We Treat

What We Treat

Diseases and Conditions

Treatments and Procedures

  • 24-hr ambulatory blood pressure monitoring
  • Central blood pressure measurements
  • Bioimpedance cardiography
  • Salt loading test
  • Clonidine suppression test

Fact Sheets & Treatment Guides

Research & Innovations

Research & Innovations

Renal Denervation Trial

Hyperactivation of the sympathetic nervous system has a major role in the initiation, development and maintenance of hypertension. In prior studies, patients undergoing selective renal denervation to attenuate sympathetic tone have been reported to have significant blood pressure reduction The Departments of Nephrology and Hypertension and Cardiology at Cleveland Clinic are participating in renal denervation trials in the US.

SPRINT Trial

The Department of Nephrology and Hypertension is involved in the NIH SPRINT (Systolic Blood Pressure Intervention Trial) to determine whether or not treating systolic blood pressure aggressively will reduce the rate of heart disease and stroke, memory decline or worsening of kidney disease in adults over the age of 50 who already have high cardiovascular risk, with participants followed long-term up to 7 years.

 

Staff

Staff

George Thomas , MD
Director, Center for Blood Pressure Disorders